Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, March 19, 2026
Rhea-AI Summary
Eton Pharmaceuticals (Nasdaq: ETON) will report fourth quarter and full year 2025 financial results on Thursday, March 19, 2026. Management will host a conference call and live audio webcast at 4:30 p.m. ET (3:30 p.m. CT).
Investors may join the participant call or webcast, submit live questions, or email questions to investorrelations@etonpharma.com. An archived webcast will be available on the company investor website approximately two hours after the event and remain for 30 days.
Positive
- None.
Negative
- None.
News Market Reaction – ETON
In the Mar 4 session, ETON gained 0.46%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| 2026-02-25 | FDA approval | Positive | -3.5% | U.S. FDA approval for DESMODA oral solution for central diabetes insipidus. |
| 2026-02-20 | Conference participation | Neutral | -1.6% | Announcement of participation in Leerink Partners Global Healthcare Conference. |
| 2026-02-02 | Licensing deal | Positive | +1.1% | Licensing of U.S. rights to an ultra-rare disease product under FDA review. |
| 2025-11-24 | Conference presentation | Neutral | +2.7% | Planned fireside chat at Piper Sandler healthcare conference. |
| 2025-11-12 | Investor meetings | Neutral | -3.3% | Planned one-on-one meetings at Craig-Hallum Alpha Select Conference. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent catalysts, including FDA approval and licensing deals, have not produced consistently positive next-day price reactions, with one notable divergence on positive FDA news.
Over the last few months, Eton reported several strategic milestones, including licensing an ultra-rare disease product candidate on Feb 2, 2026 and securing U.S. FDA approval for DESMODA on Feb 25, 2026. The company also maintained active investor outreach through multiple healthcare conferences in late 2025 and early 2026. Despite generally positive business developments, next-day price moves were mixed, including a -3.45% reaction to the DESMODA approval. Today’s earnings date announcement fits into this pattern of frequent news flow ahead of key commercial milestones.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DEER PARK, Ill., March 03, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report fourth quarter and full year 2025 financial results on Thursday, March 19, 2026. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET (3:30 p.m. CT).
Participant Call Link: Click Here
Webcast: Click Here
In addition to taking live questions from participants on the conference call, management will be answering emailed questions from investors. Investors can email questions to: investorrelations@etonpharma.com.
The live webcast can also be accessed on the Investors section of Eton’s website at https://ir.etonpharma.com/. An archived webcast will be available on Eton’s website approximately two hours after the completion of the event and for 30 days thereafter.
About Eton Pharmaceuticals
Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has ten commercial rare disease products: KHINDIVI™, INCRELEX®, ALKINDI SPRINKLE®, DESMODA™, GALZIN®, HEMANGEOL®, PKU GOLIKE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has four additional product candidates in late-stage development: Amglidia®, ET-700, ET-800 and ZENEO® hydrocortisone autoinjector. For more information, please visit our website at www.etonpharma.com.
For more information, please visit our website at www.etonpharma.com.
Investor Relations:
Lisa M. Wilson
In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com
Source: Eton Pharmaceuticals, Inc.
